AU2013355391B2 - Peptide compounds and methods of production and use thereof - Google Patents
Peptide compounds and methods of production and use thereof Download PDFInfo
- Publication number
- AU2013355391B2 AU2013355391B2 AU2013355391A AU2013355391A AU2013355391B2 AU 2013355391 B2 AU2013355391 B2 AU 2013355391B2 AU 2013355391 A AU2013355391 A AU 2013355391A AU 2013355391 A AU2013355391 A AU 2013355391A AU 2013355391 B2 AU2013355391 B2 AU 2013355391B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- peptide
- cap37
- composition
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732750P | 2012-12-03 | 2012-12-03 | |
| US61/732,750 | 2012-12-03 | ||
| US201361812584P | 2013-04-16 | 2013-04-16 | |
| US61/812,584 | 2013-04-16 | ||
| US201361813527P | 2013-04-18 | 2013-04-18 | |
| US61/813,527 | 2013-04-18 | ||
| PCT/US2013/072884 WO2014089088A1 (en) | 2012-12-03 | 2013-12-03 | Peptide compounds and methods of production and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013355391A1 AU2013355391A1 (en) | 2015-07-23 |
| AU2013355391B2 true AU2013355391B2 (en) | 2017-08-03 |
Family
ID=50883940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013355391A Active AU2013355391B2 (en) | 2012-12-03 | 2013-12-03 | Peptide compounds and methods of production and use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9603896B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2925341B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6377070B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013355391B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2893504C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2925341T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014089088A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096679B2 (en) | 2012-12-03 | 2015-08-04 | The Board Of Regents Of The University Of Oklahoma | Peptide compounds and methods of production and use thereof |
| JP6405365B2 (ja) | 2013-04-16 | 2018-10-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ | ペプチド化合物及びその製造方法及びその使用 |
| US20200157159A1 (en) | 2013-04-16 | 2020-05-21 | The Board Of Regents Of The University Of Oklahoma | Peptide compounds and compositions thereof |
| CN106397456B (zh) * | 2016-08-31 | 2019-05-07 | 成都倍特药业有限公司 | 一种含高纯度头孢地尼的组合物及其精制方法 |
| EP3802568A4 (en) | 2018-06-08 | 2022-07-13 | The Board of Regents of the University of Oklahoma | PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES |
| CN117586376A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效胰岛素化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6107460A (en) | 1999-03-01 | 2000-08-22 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use thereof |
| WO2002042259A2 (en) * | 2000-11-27 | 2002-05-30 | University Of Maryland, Baltimore | Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid |
| AU2002305845B2 (en) * | 2001-06-08 | 2006-03-30 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
| US7655480B2 (en) | 2002-03-08 | 2010-02-02 | The Board Of Regents Of The University Of Oklahoma | Method for predicting sepsis or an acute infectious inflammatory response |
| US8450071B2 (en) | 2002-03-08 | 2013-05-28 | The Board Of Regents Of The University Of Oklahoma | Biomarker and method for detecting a chronic inflammatory-associated disease |
| AU2003220034A1 (en) | 2002-03-08 | 2003-09-22 | Heloise, Anne, Pereira, Ph. D. | An early detection marker for chronic inflammatory associated diseases |
| US7354900B2 (en) * | 2002-05-03 | 2008-04-08 | The Board Of Regents Of The University Of Oklahoma | Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| CN101300022A (zh) | 2005-08-01 | 2008-11-05 | 俄克拉荷马州大学评议会 | 抗真菌肽和其使用方法 |
| US9399675B2 (en) | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
| WO2011103567A2 (en) | 2010-02-22 | 2011-08-25 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Peptides and methods for inducing cell death |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
-
2013
- 2013-12-03 US US14/649,485 patent/US9603896B2/en active Active
- 2013-12-03 AU AU2013355391A patent/AU2013355391B2/en active Active
- 2013-12-03 DK DK13859680.4T patent/DK2925341T3/en active
- 2013-12-03 JP JP2015546558A patent/JP6377070B2/ja active Active
- 2013-12-03 WO PCT/US2013/072884 patent/WO2014089088A1/en not_active Ceased
- 2013-12-03 EP EP13859680.4A patent/EP2925341B1/en active Active
- 2013-12-03 CA CA2893504A patent/CA2893504C/en active Active
-
2016
- 2016-06-03 US US15/172,695 patent/US20160317617A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| PEREIRA ET AL., "CAP37, a neutrophil granule-derived protein stimulates protein kinase C activity in endothelial cells", JOURNAL OF LEUKOCYTE BIOLOGY, (199609), vol. 60, pages 415 - 422 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9603896B2 (en) | 2017-03-28 |
| CA2893504A1 (en) | 2014-06-12 |
| WO2014089088A1 (en) | 2014-06-12 |
| DK2925341T3 (en) | 2018-05-07 |
| EP2925341B1 (en) | 2018-01-31 |
| EP2925341A4 (en) | 2016-10-05 |
| US20150374785A1 (en) | 2015-12-31 |
| CA2893504C (en) | 2016-11-22 |
| AU2013355391A1 (en) | 2015-07-23 |
| EP2925341A1 (en) | 2015-10-07 |
| US20160317617A1 (en) | 2016-11-03 |
| JP6377070B2 (ja) | 2018-08-22 |
| JP2016501889A (ja) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160317617A1 (en) | Peptide Compounds and Methods of Production and Use Thereof | |
| US9862748B2 (en) | Peptide compounds and methods of production and use thereof | |
| JP2023539476A (ja) | アネキシンa1のn末端ペプチド製剤及び方法 | |
| AU2018249816B2 (en) | Mineral coated microparticles for sustained delivery of biologically active molecules | |
| US20180208633A1 (en) | Peptide Compounds and Methods of Production and Use Thereof | |
| EP3802568A1 (en) | Peptide therapeutics for treating alzheimer's disease and related conditions | |
| JP2016501889A5 (cg-RX-API-DMAC7.html) | ||
| US11884710B2 (en) | Peptide compounds and methods of use in wound healing | |
| JP6042106B2 (ja) | メチオニン・スルホキシドを含む新規ポリペプチド | |
| AU2006275417B2 (en) | Antifungal peptides and methods of use thereof | |
| KR102609115B1 (ko) | 펩타이드를 포함하는 안구 질환의 치료용 조성물 | |
| WO2024064288A1 (en) | Tlr4 inhibitors for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PEREIRA, H. ANNE; KASUS-JACOBI, ANNE AND GRIFFITH, GINA L. |
|
| FGA | Letters patent sealed or granted (standard patent) |